Table 1.
Patient information
| GVHD patient no. | 1 | 2 | 3 | 4 | 5 | 6 | 7 |
|---|---|---|---|---|---|---|---|
| Age (y) | 30–39 | 20–29 | 20–29 | 50–59 | 40–49 | 50–59 | 0–9 |
| Sex | 1 | 2 | 1 | 1 | 1 | 1 | 1 |
| Diagnosis | ALL | AML | AA | AML | ALL | ALL | AA |
| Stem cell source | HSC and PBSC | HSC and PBSC | HSC and PBSC | HSC and PBSC | HSC and PBSC | HSC and PBSC | HSC and PBSC |
| GVHD prophylaxis | Tacrolimus | Tacrolimus and cyclosporine A | Cyclosporine A | Cyclosporine A and mycophenolic acid and methotrexate | Cyclosporine A and mycophenolic acid and methotrexate | Cyclosporine A and mycophenolic acid | Cyclosporine A |
| Match | MFD | MFD | MFD | MFD | MFD | MFD | MFD |
| Concomitant drug therapy | Tacrolimus | Tacrolimus | Cyclosporine A | Methylprednisolone and cyclosporine A | Cyclosporine A | Cyclosporine A | Cyclosporine A |
ALL acute lymphoblastic leukemia, AML acute myelocytic leukemia, AA aplastic anemia, HSC hematopoietic stem cell, PBMC peripheral blood stem cell, MFD matched familiar donor